Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era
Haematologica, Volume 97, No. 11, Year 2012
Notification
URL copied to clipboard!
Description
The role of allogeneic stem cell transplant in advanced acute promyelocytic leukemia patients who received standard first- and second-line therapy is still unknown. We report the outcome of 31 acute promyelocytic leukemia patients (median age 39 years) who underwent allogeneic transplant in second remission (n=15) or beyond (n=16). Sixteen patients were real-time polymerase chain reaction positive and 15 negative for PML/RARA pre-transplant. The 4-year overall survival was 62% and 31% for patients transplanted in second remission and beyond, respectively (P=0.05), and 64% and 27% for patients with pre-transplant negative and positive real-time polymerase chain reaction, respectively (P=0.03). The 4-year cumulative incidence of relapse was 32% and 44% for patients transplanted in second remission and beyond, respectively (P=0.37), and 30% and 47% for patients transplanted with negative and positive real-time polymerase chain reaction, respectively (P=0.30). Transplantrelated mortality was 19.6%. In conclusion, allogeneic transplant is effective in advanced acute promyelocytic leukemia in the all-trans-retinoic acid and arsenic trioxide era, and should be considered once relapse is diagnosed. ©2012 Ferrata Storti Foundation.
Authors & Co-Authors
Ramadan, Safaa M.
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Egypt, Giza
Cairo University
Veroli, Ambra Di
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Camboni, Agnese
Italy, Genoa
Irccs San Martino Polyclinic Hospital
Breccia, Massimo
Italy, Rome
Sapienza Università Di Roma
Iori, Anna Paola
Italy, Rome
Sapienza Università Di Roma
Aversa, Franco
Italy, Perugia
Università Degli Studi Di Perugia
Cupelli, Luca
Italy, Rome
Ospedale S. Eugenio
Papayannidis, Cristina
Italy, Bologna
Alma Mater Studiorum Università Di Bologna
Bacigalupo, Andrea A.
Italy, Genoa
Irccs San Martino Polyclinic Hospital
Arcese, William
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Lo-Coco, Francesco
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Italy, Rome
Irccs Fondazione Santa Lucia
Statistics
Citations: 20
Authors: 11
Affiliations: 8
Identifiers
Doi:
10.3324/haematol.2012.065714
ISSN:
03906078
e-ISSN:
15928721
Study Design
Cohort Study